Related Experiment Video

Updated: Aug 19, 2026

Real-time Evaluation of Absolute, Cytosolic, Free Ca2+ and Corresponding Contractility in Isolated, Pressurized Lymph Vessels
08:46

Real-time Evaluation of Absolute, Cytosolic, Free Ca2+ and Corresponding Contractility in Isolated, Pressurized Lymph Vessels

Published on: March 22, 2024

Use of nifedipine in the treatment of hypertension

Roberto Pontremoli1, Giovanna Leoncini, Angelica Parodi

  • 1University of Genoa, Department of Internal Medicine, Viale Benedetto XV, 6-16132 Genoa, Italy. roberto.pontremoli@unige.it

Expert Review of Cardiovascular Therapy
|February 23, 2005
PubMed

Insights

Extended-release nifedipine effectively lowers blood pressure and offers cardiovascular protection in hypertensive patients. This dihydropyridine calcium channel blocker shows benefits comparable to diuretics with fewer metabolic issues.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Hypertension is a major modifiable risk factor for cardiovascular disease globally.
  • Effective antihypertensive drugs are crucial for reducing cardiovascular morbidity and mortality.
  • Dihydropyridine calcium channel blockers are well-tolerated and play a key role in hypertension management.

Purpose of the Study:

  • To review the clinical evidence supporting the use of nifedipine in treating hypertension.
  • To highlight the efficacy and safety profile of extended-release nifedipine.
  • To discuss the cardiovascular protective effects of nifedipine.

Main Methods:

  • Review of clinical evidence and studies, including the International Nifedipine gastrointestinal therapeutic system Study (INSIGHT).
  • Analysis of nifedipine's effects on blood pressure, cardiovascular outcomes, and atherosclerosis progression.
  • Evaluation of comparative efficacy and safety against other antihypertensive agents like diuretics.

Main Results:

  • Extended-release nifedipine effectively reduces blood pressure with a consistent concentration profile.
  • The INSIGHT study demonstrated nifedipine's cardiovascular protection is equivalent to diuretics in high-risk patients.
  • Nifedipine use was associated with a lower incidence of adverse metabolic consequences compared to diuretics.
  • Substudies showed nifedipine prevents carotid atherosclerosis progression and reduces coronary calcification worsening.

Conclusions:

  • Nifedipine is an effective treatment for hypertension, offering significant cardiovascular protection.
  • Extended-release nifedipine is a valuable therapeutic option, particularly for high-risk hypertensive patients.
  • The evidence supports the use of calcium channel blockers like nifedipine in comprehensive hypertension management.

Related Concept Videos

Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...